Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of rocatinlimab in adults with prurigo nodularis
2024-510753-10-00Phase 3Completed
- Sponsor
- Amgen
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 30
01
Overview
Phase 3, randomised, double-blind trial in prurigo nodularis (PN) comparing Rocatinlimab with Placebo for AMG 451 (2 arms). Primary endpoint: Reduction from baseline in weekly average of daily itching score. Started Nov 2024; status: completed.
02
Drugs
rocatinlimab
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on 2024-510753-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510753-10-00.